Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate glycemic control among women with gestational diabetes mellitus (GDM) under insulin versus metformin (with or without insulin supplementation), and to identify metformin poor responders requiring supplemental insulin. Methods: In Ain Shams University Hospital, mothers with 26–32‐week GDM pregnancies, failing diet control, were randomized to receive metformin (n = 47) or insulin (n = 48). The primary outcome was glycemic control. Secondary outcomes included maternal weight, parameters predicting successful metformin monotherapy, neonatal hypoglycemia, and birthweight. Results: Women using metformin (23.4% needing supplemental insulin) gained less weight (P < 0.001), and had lower fasting glucose during the first and last 2 weeks of treatment (P = 0.014 and 0.008, respectively) when compared with insulin monotherapy. Insulin supplementation in the metformin group was related to initial body mass index, HbA1c, oral glucose tolerance test (GTT), and first week mean glucose level. The 1‐h glucose level during initial GTT (Hr1‐GTT) and the mean fasting glucose level during the first week of therapy (Wk1‐mFG) were the two independent parameters associated with requiring supplemental insulin. Women with Hr1‐GTT >212 mg/dL and Wk1‐mFG >95 mg/dL had a risk ratio of 58.6 (95%CI: 3.68–933.35, P = 0.004) and 11.5 (95%CI: 2.77–47.34,= 0.0008), respectively for needing supplemental insulin during the course of the study compared with women without. Conclusion: Metformin is an effective and safe alternative to insulin in GDM. Women using metformin (± supplemental insulin) had similar glycemic control, less weight gain, and similar rates of side‐effects as those on insulin monotherapy. Insulin supplementation to metformin therapy was more likely with elevated Hr1‐GTT and Wk1‐mFG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s88 · Cited by 916
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
Randomized trial of metformin vs insulin in the management of gestational diabetes
Spaulonci, C. P., Bernardes, L. S., Trindade, T. C., Zugaib, M., & Francisco, R. P. V. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.022 · Cited by 183
Cited by
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002848 · Cited by 251
Insulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L., Williamson, K., Downie, M. R., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037.pub2 · Cited by 158
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003126 · Cited by 73
The emerging role of metformin in gestational diabetes mellitus
Gray, S. G., McGuire, T. M., Cohen, N., & Little, P. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12893 · Cited by 40
Caissutti, C., Saccone, G., Khalifeh, A., Mackeen, A. D., Lott, M., & Berghella, V. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1449203 · Cited by 13
Metadata
- Authors
- Ashoush, S., El‐Said, M., Fathi, H., & Abdelnaby, M.
- Venue
- Journal of Obstetrics and Gynaecology Research
- Publisher
- Wiley
- Published
- 2016-03-15
- Volume
- 42
- Issue
- 6
- Pages
- 640-647
- ISSN
- 1341-8076 (ISSN-L)
- 1447-0756
- OpenAlex
- W2297880637
- Cited by
- 80
- References
- 4
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.